WAKAMOTO PHARMACEUTICAL CO.,LTD.
4512わかもと製薬株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-13For the first half of the fiscal year to 2026-03: Revenue ¥4.4 billion (+15.0% YoY), Ordinary income ¥-0.2 billion, Net income ¥-0.1 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥4.4bn | +15.0% |
| Ordinary profit | −¥176m | — |
| Net profit to owners | −¥134m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4512/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2026-03-31- Revenue
- ¥9.9bn
- Net income
- ¥227m
- ROE
- 1.9%
- Equity ratio
- 72.8%
- Dividend / share
- ¥3.5
- Employees
- 303
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥9.9bn | ¥0.2bn | ¥16.5bn | ¥12.0bn | 1.9% | ¥6.54 | −¥0.5bn |
| 2025-03-31 | ¥7.8bn | ¥0.1bn | ¥15.0bn | ¥11.6bn | 0.6% | ¥1.85 | −¥0.6bn |
| 2024-03-31 | ¥7.7bn | ¥0.1bn | ¥15.4bn | ¥12.0bn | 0.9% | ¥3.13 | −¥0.1bn |
| 2023-03-31 | ¥8.7bn | ¥0.1bn | ¥15.7bn | ¥11.9bn | 1.2% | ¥3.98 | ¥0.6bn |
| 2022-03-31 | ¥8.4bn | ¥0.2bn | ¥15.0bn | ¥11.5bn | 2.1% | ¥6.87 | ¥0.3bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 1.92 | 10.7 |
| Ordinary margin | 0.0259 | 20.9 |
| Equity ratio, % | 72.78 | 79.4 |
| Revenue growth | 0.2718 | 92.5 |
| Net income growth | 2.526 | 94.7 |
| Operating cash flow / assets | -0.0295 | 10.5 |
Results wording balance: 0.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥400m of reported debt repriced by 50 basis points, a year's interest would rise by ¥2m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4512/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4512/votingOwnership changes
All companies →- 2026-08-27
Asset Value Investors Limited raised holdings in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) to 11.64% from 10.60%.
- 2026-01-09
Asset Value Investors Limited raised holdings in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) to 10.60% from 9.58%.
- 2026-01-09
Holdings of Asset Value Investors Limited in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) moved above 10% (9.58% -> 10.60%).
- 2025-05-29
Asset Value Investors Limited raised holdings in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) to 9.58% from 8.54%.
- 2025-04-01
Asset Value Investors Limited raised holdings in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) to 8.54% from 7.45%.
- 2025-03-07
Asset Value Investors Limited raised holdings in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) to 7.45% from 6.14%.
- 2025-02-27
Asset Value Investors Limited states it may make proposals to the management of WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) (first filing).
- 2025-02-27
Asset Value Investors Limited disclosed a 6.14% stake in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512), crossing the 5% reporting threshold.
- 2025-02-13
ROHTO PHARMACEUTICAL CO.,LTD. disclosed a 11.40% stake in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512), crossing the 5% reporting threshold.
- 2025-02-13
Holdings of ROHTO PHARMACEUTICAL CO.,LTD. in WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) moved above 10% (new -> 11.40%).
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Asset Value Investors Limited | 2025-02-18 – 2026-08-20 | +3,702,000 | +10.57pt | ¥299.16 | ¥255–338 |
| ロート製薬株式会社 | 2025-02-06 – 2025-02-06 | +2,866,900 | +8.23pt | ¥215 | ¥215–215 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4512/trades.
5% filings
Large shareholding reports on 4512| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-08-27 | Asset Value Investors Limited | 11.64% | +1.04pt | may make proposals pure investment |
| 2026-01-09 | Asset Value Investors Limited | 10.60% | +1.02pt | may make proposals pure investment |
| 2025-05-29 | Asset Value Investors Limited | 9.58% | +1.04pt | may make proposals pure investment |
| 2025-04-01 | Asset Value Investors Limited | 8.54% | +1.09pt | may make proposals pure investment |
| 2025-03-07 | Asset Value Investors Limited | 7.45% | +1.31pt | may make proposals pure investment |
| 2025-02-27 | Asset Value Investors Limited | 6.14% | — | may make proposals pure investment |
| 2025-02-13 | ROHTO PHARMACEUTICAL CO.,LTD. | 11.40% | — | — |
| 2021-11-08 | Mizuho Bank,Ltd. | 4.57% | −0.68pt | — |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 14 issues
- Book value
- ¥2.2bn
- Sold in the year
- — — issues
- Bought in the year
- ¥3m 2 issues
- Mutual, both reports
- 10
- Held by listed cos.
- 15
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| KISSEI PHARMACEUTICAL CO.,LTD. 4547 | ¥930m | 0.0% | both reports |
| ROHTO PHARMACEUTICAL CO.,LTD. 4527 | ¥524m | 0.0% | both reports |
| 養命酒製造㈱ 2540 | ¥253m | 0.0% | both reports |
| OHKI HEALTHCARE HOLDINGS CO.,LTD. 3417 | ¥126m | +2.6% | both reports |
| Mizuho Financial Group, Inc. 8411 | ¥118m | 0.0% | stated |
| SUZUKEN CO.,LTD. 9987 | ¥110m | 0.0% | both reports |
| Mitsubishi UFJ Financial Group, Inc. 8306 | ¥85m | 0.0% | stated |
| ㈱ほくやく・竹山ホールディングス | ¥29m | 0.0% | stated |
| ASAHI PRINTING CO.,LTD. 3951 | ¥28m | 0.0% | both reports |
| Kyodo Printing Co., Ltd. 7914 | ¥13m | 0.0% | both reports |
Held by: ROHTO PHARMACEUTICAL CO.,LTD. 4527, KISSEI PHARMACEUTICAL CO.,LTD. 4547, Kyodo Printing Co., Ltd. 7914, ASAHI PRINTING CO.,LTD. 3951, SUZUKEN CO.,LTD. 9987, 2540 2540, TSUMUGU Holdings, Inc. 3055, DAIKIN INDUSTRIES, LTD. 6367, TAUNS Laboratories, Inc. 197A, Astena Holdings Co., Ltd. 8095, NIPRO CORPORATION 8086, Daito Pharmaceutical Co., Ltd. 4577 and 3 more
Purposes, all holdings and mutual flags via /v1/companies/4512/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| ロート製薬株式会社 | 3,971,000 | 11.44% |
| キッセイ薬品工業株式会社 | 3,778,000 | 10.89% |
| AVI JAPAN OPPORTUNITY TRUST PLC | 2,998,000 | 8.64% |
| 株式会社ブレストシーブ | 2,500,000 | 7.20% |
| わかもと製薬取引先持株会 | 2,012,000 | 5.80% |
| 朝日生命保険相互会社 | 1,204,000 | 3.47% |
| 日本ゼトック株式会社 | 1,201,000 | 3.46% |
| 株式会社みずほ銀行 | 1,093,000 | 3.15% |
| SG／UCITS V／INV（常任代理人 香港上海銀行東京支店 セキュリティーズ・サービシズ・オペレーションズ | 867,000 | 2.50% |
| アクサ生命保険株式会社 | 789,000 | 2.28% |
Get this as JSON
GET /v1/companies/4512
GET /v1/companies/4512/financials
GET /v1/companies/4512/details
GET /v1/companies/4512/segments
GET /v1/companies/4512/voting
GET /v1/companies/4512/tender-offers
GET /v1/companies/4512/indicators
GET /v1/companies/4512/earnings-releases
GET /v1/events?ticker=4512
GET /v1/companies/4512/trades
GET /v1/companies/4512/cross-holdings
GET /v1/companies/4512/brief